explore -WSS

explore

author：leisure time 2025-09-29 20:51:41 - browse：6825

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： FDA needs staff influx to meet gene therapy needs, Marks says

WSS

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Physician groups backed by private equity giant lobby on mergers

Radiology is caught between AI's potential and concern for patients

Teach medical students about patients with intellectual disabilities

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

hotspot

explore

Gilead needs Arcellx more than ever

focus

Continuity nursing helped my family in our darkest PICU moments

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

How one medical school became remarkably diverse

Vertex non

The high cost of giving birth even with insurance

Wildfire pollution widens asthma inequities on Long Island

Moonlake's readout produced a cash windfall. Risks remain

Trump indictment: Who are the 'co

hotspot

Americans' trust in science, scientist continues decline: Report

What causes an itch? Researchers may have solved the mystery

‘Oppenheimer’ and the risks of AI in health care

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Radiology is caught between AI's potential and concern for patients

Pfizer plans to depart BIO

focus

Wikipedia

entertainment

hotspot